SILVERARC CAPITAL MANAGEMENT, LLC — 13F Holdings & Portfolio
CIK 1816307 · latest 13F-HR filed 2026-08-13
SILVERARC CAPITAL MANAGEMENT, LLC manages $962.2M in 13F-reported U.S. long-equity assets across 73 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are ASND (5.72%), CELC (5.45%), COGT (5.15%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 20 new positions and exited 22; 23 existing positions rose in reported value and 15 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-13
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- ORUKA THERAPEUTICS INC$26.2M +353.6%
- UROGEN PHARMA LTD$20.9M +77.3%
- IMMUNOVANT INC$13.6M +131.8%
- VERACYTE INC$12.9M +222.7%
- CELCUITY INC$11.6M +28.3%
Top Trims
- DIANTHUS THERAPEUTICS INC-$16.9M -30.8%
- KODIAK SCIENCES INC-$16.5M -43.7%
- ABIVAX SA-$11.1M -32.9%
- ALKERMES PLC-$10.3M -63.5%
- ZENAS BIOPHARMA INC-$9.3M -41.7%
New Positions
- ASCENDIS PHARMA A/S$55.0M
- ENLIVEN THERAPEUTICS INC$24.8M
- SAGIMET BIOSCIENCES INC$22.6M
- DEFINIUM THERAPEUTICS INC$18.8M
- ALX ONCOLOGY HLDGS INC$11.9M
Exited Positions
- KALVISTA PHARMACEUTICALS INC$57.9M
- NUVALENT INC$36.4M
- ASCENDIS PHARMA A/S$28.5M
- CENTESSA PHARMACEUTICALS PLC$18.5M
- SCHOLAR ROCK HLDG CORP$16.7M
SILVERARC CAPITAL MANAGEMENT, LLC Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | ASCENDIS PHARMA A/S | ASND | K08588103 | $55.0M | 5.72% | 206,234 | SH |
| 2 | CELCUITY INC | CELC | 15102K100 | $52.4M | 5.45% | 500,996 | SH |
| 3 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $49.6M | 5.15% | 1,280,707 | SH |
| 4 | UROGEN PHARMA LTD | URGN | M96088105 | $47.9M | 4.98% | 1,301,979 | SH |
| 5 | IMMUNOME INC | IMNM | 45257U108 | $42.7M | 4.44% | 2,017,009 | SH |
| 6 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $38.0M | 3.95% | 390,000 | SH |
| 7 | RHYTHM PHARMACEUTICALS INC | RYTM | 76243J105 | $34.6M | 3.59% | 311,461 | SH |
| 8 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $33.6M | 3.49% | 352,802 | SH |
| 9 | MONTE ROSA THERAPEUTICS INC | GLUE | 61225M102 | $26.8M | 2.79% | 1,108,295 | SH |
| 10 | SYNDAX PHARMACEUTICALS INC | SNDX | 87164F105 | $26.5M | 2.76% | 1,214,390 | SH |
| 11 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $24.8M | 2.58% | 489,382 | SH |
| 12 | IMMUNOVANT INC | IMVT | 45258J102 | $23.9M | 2.48% | 619,096 | SH |
| 13 | ERASCA INC | ERAS | 29479A108 | $23.1M | 2.40% | 1,263,026 | SH |
| 14 | SAGIMET BIOSCIENCES INC | SGMT | 786700104 | $22.6M | 2.35% | 2,927,698 | SH |
| 15 | ABIVAX SA | ABVX | 00370M103 | $22.6M | 2.35% | 169,593 | SH |
| 16 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $22.0M | 2.29% | 65,679 | SH |
| 17 | KODIAK SCIENCES INC | KOD | 50015M109 | $21.3M | 2.21% | 546,256 | SH |
| 18 | ARK ETF TR Put | ARKE | 00214Q952 | $21.0M | 2.19% | 500,000 | SH |
| 19 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $18.8M | 1.96% | 400,000 | SH |
| 20 | VERACYTE INC | VCYT | 92337F107 | $18.7M | 1.94% | 318,001 | SH |
| 21 | SYNDAX PHARMACEUTICALS INC Call | SNDX | 87164F905 | $15.2M | 1.58% | 693,600 | SH |
| 22 | GUARDANT HEALTH INC | GH | 40131M109 | $15.0M | 1.56% | 99,826 | SH |
| 23 | C4 THERAPEUTICS INC | CCCC | 12529R107 | $14.2M | 1.47% | 3,032,060 | SH |
| 24 | ZENAS BIOPHARMA INC | ZBIO | 98937L105 | $12.9M | 1.34% | 509,789 | SH |
| 25 | TREVI THERAPEUTICS INC | TRVI | 89532M101 | $12.6M | 1.31% | 678,095 | SH |
| 26 | HELIX ACQUISITION CORP III | HLXC | G4444S107 | $12.5M | 1.30% | 1,177,821 | SH |
| 27 | ALX ONCOLOGY HLDGS INC | ALXO | 00166B105 | $11.9M | 1.24% | 5,744,757 | SH |
| 28 | VERADERMICS INC | MANE | 922967104 | $11.7M | 1.21% | 95,000 | SH |
| 29 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $11.3M | 1.17% | 186,821 | SH |
| 30 | AVALYN PHARMACEUTICALS INC | AVLN | 05348Y105 | $10.9M | 1.13% | 330,487 | SH |
| 31 | BIOGEN INC | BIIB | 09062X103 | $10.4M | 1.08% | 48,101 | SH |
| 32 | ACLARIS THERAPEUTICS INC | ACRS | 00461U105 | $10.3M | 1.07% | 1,946,482 | SH |
| 33 | CERUS CORP | CERS | 157085101 | $10.1M | 1.05% | 3,472,737 | SH |
| 34 | AVALO THERAPEUTICS INC | AVTX | 05338F306 | $9.2M | 0.96% | 500,402 | SH |
| 35 | BENITEC BIOPHARMA INC | BNTC | 08205P209 | $9.1M | 0.95% | 679,826 | SH |
| 36 | VAXCYTE INC | PCVX | 92243G108 | $8.4M | 0.88% | 145,000 | SH |
| 37 | GENEDX HOLDINGS CORP | WGS | 81663L200 | $8.4M | 0.87% | 122,269 | SH |
| 38 | SAVARA INC | SVRA | 805111101 | $8.3M | 0.87% | 1,355,459 | SH |
| 39 | OVID THERAPEUTICS INC | OVID | 690469101 | $8.3M | 0.87% | 3,101,129 | SH |
| 40 | ORIC PHARMACEUTICALS INC | ORIC | 68622P109 | $8.0M | 0.83% | 738,873 | SH |
| 41 | ORIC PHARMACEUTICALS INC Call | ORIC | 68622P909 | $7.4M | 0.77% | 682,600 | SH |
| 42 | MONTE ROSA THERAPEUTICS INC Call | GLUE | 61225M902 | $7.3M | 0.75% | 300,000 | SH |
| 43 | COMPASS PATHWAYS PLC | CMPS | 20451W101 | $7.1M | 0.74% | 503,382 | SH |
| 44 | COMPUGEN LTD | CGEN | M25722105 | $6.8M | 0.71% | 3,184,257 | SH |
| 45 | SOLID BIOSCIENCES INC | SLDB | 83422E204 | $6.7M | 0.69% | 668,450 | SH |
| 46 | ABIVAX SA Call | AAVXF | 00370M903 | $6.7M | 0.69% | 50,000 | SH |
| 47 | IBIO INC | IBIO | 451033708 | $6.2M | 0.64% | 3,520,490 | SH |
| 48 | DISC MEDICINE INC | IRON | 254604101 | $6.1M | 0.63% | 82,800 | SH |
| 49 | ALKERMES PLC | ALKS | G01767105 | $5.9M | 0.62% | 113,494 | SH |
| 50 | SPYRE THERAPEUTICS INC | SYRE | 00773J202 | $5.3M | 0.55% | 59,959 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-13 | $962.2M | 73 | 0001420506-26-001563 |
| 2026-03-31 | 2026-05-14 | $979.8M | 73 | 0001420506-26-001011 |
| 2025-12-31 | 2026-02-12 | $720.1M | 68 | 0001420506-26-000321 |
| 2025-09-30 | 2025-11-12 | $741.6M | 82 | 0001420506-25-003142 |
SUITE 620
BOSTON, MA 02116